<DOC>
	<DOCNO>NCT00287131</DOCNO>
	<brief_summary>Metastatic melanoma aggressive highly malignant cancer . The five-year survival rate patient metastatic disease le 5 % median survival 6-10 month . Drugs like Dacarbazin ( DTIC ) single agent combination chemotherapy agent , response rate 15-30 % , duration response usually short , impact survival . Interleukin-2 ( IL-2 ) base immunotherapy show promising result . This form therapy similar response rate patient achieve durable complete response . Recently National Institute Health ( NIH ) report use lympho-depleting chemotherapy , follow adoptive transfer large number anti-tumor specific tumor-infiltrating lymphocyte ( TIL ) , objective regression achieve 51 % patient metastatic melanoma . Objectives : To introduce TIL technology advance metastatic melanoma patient Israel .</brief_summary>
	<brief_title>Adoptive Cell Therapy Following Non-myeloablate Chemotherapy Metastatic Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Metastatic Melanoma patient fail prior chemo immunotherapy good performance status . Brain mets</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>melanoma</keyword>
	<keyword>metastatic melanoma</keyword>
	<keyword>adoptive immunotherapy</keyword>
	<keyword>IL-2</keyword>
</DOC>